Analyst Favors Cigna, Alignment Healthcare, Cautious On Peers

Cigna's Evernorth Health Services has invested $3.5 billion in Shields Health Solutions via preferred stock, a move not expected to materially impact Cigna's 2025 adjusted EPS guidance of at least $29.60. This investment coincided with Shields becoming a private, standalone company following its acquisition by Sycamore Partners from Walgreens. BofA Securities maintains a positive outlook on Cigna, projecting 10-15% annual EPS growth and a 9% FCF yield, citing its pure-play commercial insurer status and broad exposure to rising drug spending. The firm views Cigna as having less downside risk compared to peers like UnitedHealth and Centene, on which BofA is more cautious due to specific regulatory and market headwinds.

Analysis

Cigna Group's Evernorth Health Services has made a significant strategic investment of $3.5 billion in Shields Health Solutions through preferred stock. This transaction, which coincides with Shields' acquisition by Sycamore Partners from Walgreens, is not expected to materially alter Cigna's 2025 adjusted EPS guidance of at least $29.60. According to BofA Securities, Cigna stands out as the only managed care organization (MCO) to maintain its long-term EPS growth outlook, projecting an annual increase of 10-15%. This positive view is underpinned by Cigna's positioning as a pure-play commercial insurer with substantial pharmacy benefits and specialty drug businesses, which provide broad exposure to high-growth areas like obesity treatments and gene therapies without single-product risk. The company's financial profile is further supported by a 9% free cash flow yield. Crucially, Cigna is seen as avoiding the specific regulatory risks pressuring its peers; BofA remains cautious on UnitedHealth due to a potential $6 billion V28 headwind and on Centene over margin concerns from possible Medicaid work requirements. This positions Cigna with a favorable risk-reward profile, offering an estimated 25-30% upside in a sector rally but with considerably less downside risk compared to its competitors.

Key Decisions for Investors

• Investors may consider Cigna a core defensive-growth holding within the managed care sector, given its projected 10-15% annual EPS growth, strong 9% FCF yield, and relative insulation from the regulatory headwinds affecting peers.
• The diverging outlooks for Cigna versus UnitedHealth and Centene suggest potential for relative value strategies, favoring a long position in Cigna given its stronger fundamental and regulatory positioning.
• Monitor the performance of Cigna's specialty pharmacy business, as the $3.5 billion investment in Shields underscores its strategic importance as a key long-term growth driver in an environment of rising specialty drug spending.